Loomis Sayles & Co. L P Purchases 21,867 Shares of Haemonetics Corporation $HAE

Loomis Sayles & Co. L P increased its position in shares of Haemonetics Corporation (NYSE:HAE) by 11.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 217,648 shares of the medical instruments supplier’s stock after buying an additional 21,867 shares during the period. Loomis Sayles & Co. L P’s holdings in Haemonetics were worth $16,239,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of HAE. GAMMA Investing LLC lifted its position in Haemonetics by 59.4% during the 2nd quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 165 shares during the last quarter. Quarry LP grew its position in shares of Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Haemonetics by 91.7% in the second quarter. UMB Bank n.a. now owns 669 shares of the medical instruments supplier’s stock worth $50,000 after purchasing an additional 320 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in shares of Haemonetics during the 2nd quarter worth about $64,000. Finally, Parkside Financial Bank & Trust grew its holdings in Haemonetics by 11.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock valued at $109,000 after buying an additional 152 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on HAE shares. BTIG Research reiterated a “buy” rating and set a $88.00 price target on shares of Haemonetics in a report on Friday, November 21st. Raymond James Financial reiterated an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, November 25th. Barrington Research upped their price objective on shares of Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Citigroup reduced their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.70.

Haemonetics Price Performance

NYSE:HAE opened at $81.35 on Monday. The stock has a market capitalization of $3.81 billion, a PE ratio of 24.88, a P/E/G ratio of 0.91 and a beta of 0.43. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $88.86. The firm has a fifty day simple moving average of $58.57 and a 200 day simple moving average of $63.31. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. The firm had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, research analysts expect that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.